Get the Stockscreener App
72.79
5.78%
-4.4415
Nuvalent Inc stock is traded at $72.79, with a volume of 224.32K.
It is down -5.78% in the last 24 hours and down -6.63% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$77.23
Open:
$76.74
24h Volume:
224.32K
Relative Volume:
0.43
Market Cap:
$4.84B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-18.66
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
-7.13%
1M Performance:
-6.63%
6M Performance:
-15.07%
1Y Performance:
+7.89%
1-Day Range:
$72.06
$77.56
1-Week Range:
$72.06
$80.15
52-Week Range:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
72.85 | 5.65B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.43 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.36 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.06 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.26 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.09 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent's 2025 Momentum: Catalysts, Commercial Readiness, and Cash Runway Positioning for a Breakout Year - AInvest
Nuvalent (NUVL) Q2 R&D Up 65% - The Motley Fool
Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug By Investing.com - Investing.com Australia
Earnings Flash (NUVL) Nuvalent Posts Q2 Net Loss Per Share $1.39, vs. FactSet Est of $1.22 - MarketScreener
Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug - Investing.com
Nuvalent, Inc. SEC 10-Q Report - TradingView
Nuvalent's Dual Victory: FDA Rolling Review for ROS1 Cancer Drug While Phase 3 Trial Advances New ALK Treatment - Stock Titan
Analysts' Bullish Sentiments on Healthcare Companies: Avantor, Nuvalent, and Alphatec Holdings - AInvest
What catalysts could drive Nuvalent Inc. stock higher in 2025Build wealth faster with consistent growth stocks - Jammu Links News
What makes Nuvalent Inc. stock price move sharplyInvest confidently with professional market insights - Jammu Links News
Is Nuvalent Inc. a growth stock or a value stockExceptional financial outcomes - Jammu Links News
How volatile is Nuvalent Inc. stock compared to the marketInvest confidently with real-time data - Jammu Links News
What is the dividend policy of Nuvalent Inc. stockDynamic investment growth - Jammu Links News
How many analysts rate Nuvalent Inc. as a “Buy”Achieve breakthrough investment performance - Jammu Links News
What institutional investors are buying Nuvalent Inc. stockFind the best stocks for sustainable growth - Jammu Links News
What is the risk reward ratio of investing in Nuvalent Inc. stockGet ahead with breakthrough trading ideas - Jammu Links News
Published on: 2025-08-03 06:27:04 - Jammu Links News
Nuvalent’s Noci sells $321k in shares - Investing.com
Why is Nuvalent Inc. stock attracting strong analyst attentionBest Dividend Report From AI Tools - jammulinksnews.com
Nuvalent Inc. stock outlook for YEARTechnical Stock Breakout Predictions Signal Entry Points - metal.it
How Nuvalent Inc. stock performs during market volatilityWeekly Hot Picks With Buy Confidence Released - beatles.ru
Will Nuvalent Inc. Stock Benefit from AI and Green Energy TrendsFast Return Equity Trade Forecast Points to Small Caps - metal.it
Nuvalent Inc. Moves Into Overbought Range Analysts CautiousDay Trading Signals With High Precision Reviewed - metal.it
How high can Nuvalent Inc. stock price go in 2025AI Screening for Swing Trade Picks Finds Momentum - metal.it
Can Traders Expect Breakout From Nuvalent Inc. This WeekSmart Trade Plans With Risk Protection Explained - metal.it
Should I hold or sell Nuvalent Inc. stock in 2025Capitalize on market momentum for maximum gains - Jammu Links News
How does Nuvalent Inc. compare to its industry peersAchieve breakthrough profits with smart strategies - Jammu Links News
Nuvalent Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingHigh Return Potential - metal.it
What are Nuvalent Inc. company’s key revenue driversHigh-velocity capital appreciation - Jammu Links News
What are analysts’ price targets for Nuvalent Inc. in the next 12 monthsInvest confidently with proven investment plans - Jammu Links News
What markets is Nuvalent Inc. expanding into Is ISPO stock a good long term investment optionExceptional ROI - Jammu Links News
Key External Factors That Drive Nuvalent Inc. Stock Price MovementsHigh Reward Swing Trades - metal.it
Is Nuvalent Inc. a good long term investmentFree Stock Selection - PrintWeekIndia
Nuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLC - Insider Monkey
What analysts say about Nuvalent Inc. stockExplosive earnings growth - PrintWeekIndia
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Jul 30 '25 |
Sale |
80.36 |
4,000 |
321,440 |
48,034 |
0.36%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):